{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:54:17Z","timestamp":1793976857906,"version":"4.8.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.blre.2024.101228","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T06:12:04Z","timestamp":1723270324000},"page":"101228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Autologous stem cell transplantation in AL amyloidosis: Muddy waters"],"prefix":"10.1016","volume":"68","author":[{"given":"Patrick","family":"Hagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.blre.2024.101228_bb0005","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.blre.2024.101228_bb0010","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv. Ther."},{"issue":"36","key":"10.1016\/j.blre.2024.101228_bb0015","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41375-018-0258-y","article-title":"Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2024.101228_bb0025","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s41375-019-0664-9","article-title":"Revisiting complete response in light chain amyloidosis","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.blre.2024.101228_bb0035","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7778","key":"10.1016\/j.blre.2024.101228_bb0045","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0140-6736(72)93014-0","article-title":"Treatment of \u201cprimary\u201d renal amyloidosis with melphalan","volume":"2","author":"Jones","year":"1972","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0050","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V52.4.818.818","article-title":"Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo","volume":"52","author":"Kyle","year":"1978","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101228_bb0055","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/art.1780290515","article-title":"Treatment of AL amyloidosis with melphalan, prednisone, and colchicine","volume":"29","author":"Benson","year":"1986","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V77.2.257.257","article-title":"Response rates and survival in primary systemic amyloidosis","volume":"77","author":"Gertz","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0065","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin. Hematol."},{"issue":"17","key":"10.1016\/j.blre.2024.101228_bb0070","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.blre.2024.101228_bb0075","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0080","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2024.101228_bb0085","first-page":"1087","article-title":"Marrow transplantation in multiple myeloma","volume":"326","author":"Mehta","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.blre.2024.101228_bb0090","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJM199110313251809","article-title":"Toward a cure for multiple myeloma?","volume":"325","author":"Barlogie","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0095","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2024.101228_bb0100","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2024.101228_bb0105","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1702643","article-title":"Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)","volume":"26","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bmt.1702005","article-title":"High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant","volume":"24","author":"Saba","year":"1999","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0115","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","article-title":"Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients","volume":"101","author":"Moreau","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0120","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4065\/81.7.880","article-title":"High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study","volume":"81","author":"Vesole","year":"2006","journal-title":"Mayo Clin. Proc."},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0125","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4065\/81.7.874","article-title":"Autologous attack on amyloidosis","volume":"81","author":"Gertz","year":"2006","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"10.1016\/j.blre.2024.101228_bb0130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.blre.2024.101228_bb0135","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","article-title":"Autologous stem cell transplantation for primary systemic amyloidosis","volume":"99","author":"Comenzo","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0002-9343(02)01208-1","article-title":"Stem cell transplantation for the management of primary systemic amyloidosis","volume":"113","author":"Gertz","year":"2002","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.blre.2024.101228_bb0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1704344","article-title":"Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome","volume":"33","author":"Mollee","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.bmt.1704539","article-title":"A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an eastern cooperative oncology group study","volume":"34","author":"Gertz","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2006.06204.x","article-title":"Outcome of autologous stem cell transplantation for AL amyloidosis in the UK","volume":"134","author":"Goodman","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0165","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +\/\u2212 thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.blre.2024.101228_bb0170","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bmt.1704691","article-title":"Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate","volume":"34","author":"Gertz","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"14","key":"10.1016\/j.blre.2024.101228_bb0175","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","article-title":"Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival","volume":"19","author":"Dispenzieri","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.blre.2024.101228_bb0180","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc072918","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"358","author":"Mehta","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0190","first-page":"92","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"358","author":"Lokhorst","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc072918","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"358","author":"Lachmann","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc072918","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"358","author":"Kumar","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0205","first-page":"92","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"358","author":"Comenzo","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","article-title":"Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis","volume":"109","author":"Wechalekar","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2024.101228_bb0215","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.3324\/haematol.2014.108191","article-title":"Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting","volume":"99","author":"Venner","year":"2014","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.blre.2024.101228_bb0220","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0225","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bmt.2010.234","article-title":"Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006","volume":"46","author":"Gertz","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.blre.2024.101228_bb0230","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.12673","article-title":"Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution","volume":"164","author":"Jimenez-Zepeda","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0235","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2012.274","article-title":"Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis","volume":"27","author":"Landau","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0240","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0245","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/bmt.2014.115","article-title":"Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up","volume":"49","author":"Parmar","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.blre.2024.101228_bb0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/bmt.2013.98","article-title":"Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115","volume":"48","author":"Sanchorawala","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.blre.2024.101228_bb0255","series-title":"Blood","first-page":"417","article-title":"Center experience and calendar year of transplantation strongly influence short term survival after autologous peripheral Blood transplantation in 1315 patients with light chain amyloidosis: An EBMT analysis","author":"Schonland","year":"2013"},{"issue":"32","key":"10.1016\/j.blre.2024.101228_bb0260","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D\u2019Souza","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0265","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.blre.2024.101228_bb0270","first-page":"1323","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. Journal of clinical oncology\u202f: official journal of the American society of","volume":"36","author":"Sidiqi","year":"2018","journal-title":"Clin. Oncol."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0275","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41409-019-0447-y","article-title":"Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis","volume":"54","author":"Gutierrez-Garcia","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0280","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/gfab189","article-title":"Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis","volume":"37","author":"Nader","year":"2022","journal-title":"Nephrology, dialysis, transplantation\u202f: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"9","key":"10.1016\/j.blre.2024.101228_bb0285","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0290","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bmt.2015.73","article-title":"Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation","volume":"50","author":"Cornell","year":"2015","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.blre.2024.101228_bb0295","first-page":"264 e261","article-title":"Bortezomib-based induction is associated with superior outcomes in light chain amyloidosis patients treated with autologous hematopoietic cell transplantation regardless of plasma cell burden","volume":"27","author":"Cornell","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0300","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clml.2019.02.009","article-title":"Autologous hematopoietic cell transplantation versus chemotherapy alone for immunoglobulin light chain amyloidosis: a retrospective study","volume":"19","author":"Miyazaki","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.blre.2024.101228_bb0305","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.bbmt.2017.05.020","article-title":"Outcomes from autologous hematopoietic cell transplantation versus chemotherapy alone for the Management of Light Chain Amyloidosis","volume":"23","author":"Oke","year":"2017","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0310","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41409-020-01136-2","article-title":"Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis","volume":"56","author":"Vaxman","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid\u202f: the international journal of experimental and clinical investigation\u202f: the official journal of the International Society of Amyloidosis"},{"issue":"9","key":"10.1016\/j.blre.2024.101228_bb0320","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2018.06.018","article-title":"Modified high-dose Melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis","volume":"24","author":"Nguyen","year":"2018","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"6","key":"10.1016\/j.blre.2024.101228_bb0325","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-014-1680-1","article-title":"Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP","volume":"100","author":"Hayashi","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0330","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101228_bb0335","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/blood-2023-185811","article-title":"Efficacy and safety of Daratumumab monotherapy in newly diagnosed patients with stage 3B light-chain amyloidosis: a phase 2 study by the European myeloma network","volume":"142","author":"Kastritis","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101228_bb0340","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","article-title":"Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis","volume":"4","author":"Staron","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13506129.2020.1802713","article-title":"Next generation flow cytometry for MRD detection in patients with AL amyloidosis","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid\u202f: the international journal of experimental and clinical investigation\u202f: the official journal of the International Society of Amyloidosis"},{"issue":"6","key":"10.1016\/j.blre.2024.101228_bb0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-021-00511-6","article-title":"Detection of minimal residual disease by next generation sequencing in AL amyloidosis","volume":"11","author":"Sarosiek","year":"2021","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.blre.2024.101228_bb0355","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2024.101228_bb0360","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ajh.26641","article-title":"Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: a 25-year longitudinal study","volume":"97","author":"Gustine","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"25","key":"10.1016\/j.blre.2024.101228_bb0365","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2024.101228_bb0370","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2024.101228_bb0375","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the amyloidosis forum cardiac working group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.blre.2024.101228_bb0380","series-title":"StatPearls [Internet]","article-title":"Six-Minute Walk Test [Updated 2023 Aug 14]","author":"Casano","year":"2024"},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0385","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"Laboratories ATSCoPSfCPF","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"20","key":"10.1016\/j.blre.2024.101228_bb0390","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/heartjnl-2021-320703","article-title":"Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis","volume":"108","author":"Cohen","year":"2022","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0395","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/13506129.2015.1102131","article-title":"The patient\u2019s perspective on the symptom and everyday life impact of AL amyloidosis","volume":"22","author":"Lin","year":"2015","journal-title":"Amyloid\u202f: the international journal of experimental and clinical investigation\u202f: the official journal of the International Society of Amyloidosis"},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0400","first-page":"1083","article-title":"Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study","volume":"31","author":"D\u2019Souza","year":"2022","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehab."},{"key":"10.1016\/j.blre.2024.101228_bb0405","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PROM.S399658","article-title":"Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the amyloidosis forum HRQOL working group","volume":"14","author":"Rizio","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"10.1016\/j.blre.2024.101228_bb0410","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/ejh.14183","article-title":"Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis","volume":"112","author":"D\u2019Souza","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.blre.2024.101228_bb0415","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1007\/s12325-023-02637-4","article-title":"Peripheral nervous, hepatic, and gastrointestinal endpoints for AL amyloidosis clinical trials: report from the amyloidosis forum multi-organ system working group","volume":"40","author":"Mauermann","year":"2023","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0420","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","article-title":"A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis","volume":"10","author":"Sidana","year":"2020","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101228_bb0425","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-140826","article-title":"Financial toxicity and impact on health-related quality of life in patients with plasma cell disorders","volume":"136","author":"Warsame","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2024.101228_bb0430","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/cer-2017-0100","article-title":"Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data","volume":"7","author":"Quock","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0435","first-page":"2355","article-title":"Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study","volume":"109","author":"Shen","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101228_bb0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137582","volume":"136","author":"Comenzo","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0445","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41409-021-01535-z","article-title":"Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis","volume":"57","author":"Furtado","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0450","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.blre.2024.101228_bb0455","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ajh.25746","article-title":"Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis","volume":"95","author":"Sidana","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0460","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ajh.26562","article-title":"Impact of bone marrow minimal residual disease status on quality of organ response in systemic AL amyloidosis","volume":"97","author":"Chakraborty","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.blre.2024.101228_bb0465","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3324\/haematol.2018.213900","article-title":"Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial","volume":"104","author":"Minnema","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2024.101228_bb0470","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/bmt.2017.47","article-title":"Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy","volume":"52","author":"Wong","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0475","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.bbmt.2019.04.024","article-title":"Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with 3 or more organs involved","volume":"25","author":"Al Saleh","year":"2019","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0480","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbmt.2017.08.031","article-title":"High-dose Melphalan and stem cell transplantation in patients on Dialysis due to immunoglobulin light-chain amyloidosis and monoclonal immunoglobulin deposition disease","volume":"24","author":"Batalini","year":"2018","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.blre.2024.101228_bb0485","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41409-019-0524-2","article-title":"Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function","volume":"54","author":"Sidiqi","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.blre.2024.101228_bb0490","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41409-018-0242-1","article-title":"High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers","volume":"53","author":"White","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0495","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41409-019-0440-5","article-title":"High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators","volume":"54","author":"Phull","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"10.1016\/j.blre.2024.101228_bb0500","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.bbmt.2018.06.017","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis patients aged 70 to 75","volume":"24","author":"Sidiqi","year":"2018","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"8","key":"10.1016\/j.blre.2024.101228_bb0505","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction therapy with Bortezomib followed by Bortezomib-high dose Melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"19","key":"10.1016\/j.blre.2024.101228_bb0510","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101228_bb0515","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41409-018-0284-4","article-title":"High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review","volume":"54","author":"Varga","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.blre.2024.101228_bb0520","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bmt.2011.152","article-title":"Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis","volume":"47","author":"Schonland","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0525","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtct.2021.10.021","article-title":"Retrospective analysis of autologous stem cell transplantation for AL amyloidosis: a study from the multiple myeloma working Group of the Japan Society for hematopoietic cell transplantation","volume":"28","author":"Fuchida","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2024.101228_bb0530","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med."},{"issue":"11","key":"10.1016\/j.blre.2024.101228_bb0535","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2018.07.010","article-title":"Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation","volume":"24","author":"Afrough","year":"2018","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"5","key":"10.1016\/j.blre.2024.101228_bb0540","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.bbmt.2019.01.007","article-title":"Induction therapy with Bortezomib and dexamethasone and conditioning with high-dose Melphalan and Bortezomib followed by autologous stem cell transplantation for immunoglobulin light chain amyloidosis: long-term follow-up analysis","volume":"25","author":"Gupta","year":"2019","journal-title":"Biology of blood and marrow transplantation\u202f: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.blre.2024.101228_bb0545","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clml.2022.10.010","article-title":"Single center experience of autologous stem cell transplantation in patients with systemic light chain amyloidosis in Korea","volume":"23","author":"Kim","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.blre.2024.101228_bb0550","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","article-title":"The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018","volume":"13","author":"Palladini","year":"2023","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.blre.2024.101228_bb0555","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/bloodadvances.2020002219","article-title":"Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis","volume":"4","author":"Basset","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:57:44Z","timestamp":1731585464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":111,"alternative-id":["S0268960X24000614"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101228","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous stem cell transplantation in AL amyloidosis: Muddy waters","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101228"}}